The role of different methods in defining cardiometabolic risk and metabolic syndrome in women with polycystic ovary syndrome

Yükleniyor...
Küçük Resim

Tarih

2023

Dergi Başlığı

Dergi ISSN

Cilt Başlığı

Yayıncı

MDPI

Erişim Hakkı

info:eu-repo/semantics/openAccess

Özet

Polycystic ovary syndrome (PCOS) is one of the most frequent endocrine illnesses, often accompanied by visceral adiposity and metabolic syndrome (MetS). Visceral adiposity is an accurate predictor of MetS and cardiometabolic risk. This study aims to evaluate different anthropometric indices that can be used in PCOS and MetS risk assessment. A total of 66 women with PCOS (50%) and 66 controls (50%) were included, and clinical and biochemical parameters were evaluated. The body mass index (BMI), body shape index (ABSI), body roundness index (BRI), dysfunctional adiposity index (DAI), lipid accumulation (LAP) index, and visceral adiposity index (VAI) were calculated. The means of all indices were higher in the PCOS group (p < 0.05). The marker with the lowest discriminatory ability for PCOS and MetS was ABSI (AUC = 0.762 and AUC = 0.714, respectively, p = 0.000). According to the multivariate logistic regression model, the VAI and WC are strong predictors of PCOS (AUC, 98%; accuracy, 92%; sensitivity, 92%; and specificity, 91%), and WC, LAP index, and BRI are strong predictors of MetS (AUC, 0.95%; accuracy, 86%; sensitivity, 83%; and specificity, 88%). The use of different anthropometric indices in the detection of PCOS and MetS may allow for early diagnosis and treatment, and are simple and cost-effective.

Açıklama

Anahtar Kelimeler

Polycystic ovary syndrome, Metabolic syndrome, Visceral adiposity, Body mass index, A body shape index, Body roundness index, Dysfunctional adiposity index, Lipid accumulation index, Visceral adiposity index

Kaynak

Life (Basel)

WoS Q Değeri

N/A

Scopus Q Değeri

Q2

Cilt

13

Sayı

10

Künye

Çakır Biçer N, Ermiş AA, Baş D. The Role of Different Methods in Defining Cardiometabolic Risk and Metabolic Syndrome in Women with Polycystic Ovary Syndrome. Life (Basel). 2023 Sep 25;13(10):1959. doi: 10.3390/life13101959. PMID: 37895341; PMCID: PMC10608420.